283 filings
Page 4 of 15
8-K
5bupu7crv4sqqm9ygs3h
23 Nov 20
Advaxis, Inc. Announces Proposed Public Offering of
4:25pm
8-K
pecwmy7p
16 Oct 20
Entry into a Material Definitive Agreement
5:05pm
8-K
slf8k35m365szqsj2b
8 Oct 20
Termination of a Material Definitive Agreement
7:00am
8-K
0tjis m5gj
29 Sep 20
Entry into a Material Definitive Agreement
8:59am
8-K
qvo bi6m3n
10 Sep 20
Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors
4:00pm
8-K
8l8xj0ww7nrie2288s
4 Sep 20
Advaxis Announces Resignation of Chief Financial Officer
4:35pm
8-K
4b466xv3
3 Aug 20
Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital
8:05am
8-K
i27 ajeiy7pgzuh9
8 May 20
Entry into a Material Definitive Agreement
4:05pm
8-K
e5trrufft
5 May 20
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
3mk0jk660087kyj9
20 Apr 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
oxf1otbc8b0 9sgfyh
10 Apr 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:00pm
8-K
pvrj vesu
13 Mar 20
Results of Operations and Financial Condition
4:00pm
8-K
8sraezt5uvrmm kdwp
27 Feb 20
Advaxis Announces Updated Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at I/O 360° Conference
4:22pm
8-K
blgobayo vv3yjsb7w3
20 Feb 20
Advaxis Announces Positive Clinical Data in Ongoing Phase 1/2 ADXS-503 Trial in NSCLC at the IASLC 2020 Targeted Therapies of Lung Cancer Meeting
4:00pm
8-K
zjnyxuouu25xe1wbb 73
14 Feb 20
Amendments to Articles of Incorporation or Bylaws
4:00pm
8-K
v1kr 10ydz
13 Feb 20
Advaxis Announces Updated Survival Data in Phase 1/2 ADXS-PSA Trial at the ASCO Genitourinary Cancers Symposium
4:00pm
8-K
chfb262ue vrwzeeorav
23 Jan 20
Advaxis, Inc. Announces Pricing of $10.5 Million Registered Direct Offering
4:05pm
8-K
e96z3ymy7wb1 f6qow8y
16 Jan 20
Other Events
11:27am
8-K
ad4jr7wxk70d61lq htr
7 Jan 20
Advaxis Announces FDA Clearance of IND for ADXS-504 for Treatment of Prostate Cancer
4:00pm
8-K
ufufksxir4isjfteitij
20 Dec 19
Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update
4:31pm